基线CD44v6阳性循环肿瘤细胞预测转移性结直肠癌患者一线治疗失败情况。
Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer.
作者信息
Nicolazzo Chiara, Loreni Flavia, Caponnetto Salvatore, Magri Valentina, Vestri Anna Rita, Zamarchi Rita, Gradilone Angela, Facchinetti Antonella, Rossi Elisabetta, Cortesi Enrico, Gazzaniga Paola
机构信息
Department of Molecular Medicine, Liquid Biopsy Unit, Sapienza University of Rome, Rome, Italy.
Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
出版信息
Oncotarget. 2020 Nov 10;11(45):4115-4122. doi: 10.18632/oncotarget.27794.
CD44v6, the CD44 isoform mostly involved in cancer cell migration and invasion, has been identified as a functional biomarker and therapeutic target in colon cancer stem cells. We here provide evidence that baseline CD44v6-positive CTC predict treatment failure in patients with metastatic colorectal cancer undergoing first-line chemotherapy. We suggest that CD44v6-positive CTC can be used to early detect intrinsic drug resistance in this cancer type.
CD44v6是主要参与癌细胞迁移和侵袭的CD44同种型，已被确定为结肠癌干细胞中的功能性生物标志物和治疗靶点。我们在此提供证据表明，基线CD44v6阳性循环肿瘤细胞可预测接受一线化疗的转移性结直肠癌患者的治疗失败。我们认为，CD44v6阳性循环肿瘤细胞可用于早期检测这种癌症类型的内在耐药性。
Zotero 插件